TY - JOUR
T1 - Evaluation of new anti-infective drugs for the treatment of acute suppurative arthritis in children
AU - Nelson, J. D.
AU - Norden, C.
AU - Mader, J. T.
AU - Calandra, G. B.
N1 - Funding Information:
Financial support: This work was supported by a contract to the Infectious Diseases Society of America from the U.S. Food and Drug Administration (no. HHS 223-88-130I).
PY - 1992/11
Y1 - 1992/11
N2 - Diagnostic criteria for bacterial suppurative arthritis include the demonstration of an inflammatory exudate by aspiration of synovial fluid and the isolation of bacteria from cultures of synovial fluid and/or blood. Clinical manifestations include joint effusion, swelling, tenderness, and pain, with or without redness of the overlying skin. Management consists of antimicrobial therapy, measures designed to relieve symptoms, surgical drainage of infected fluid, and physical therapy. Studies of new anti-infective therapy should be limited to cases of bacterial origin. Prospective, randomized, double-blind or evaluator-blinded, active-control comparative clinical trials should be performed. Clinical response is characterized as success (cure), failure, or indeterminate outcome. The most common successful microbiological outcome is presumptive eradication. Follow-up should continue for 1 year before the final assessment.
AB - Diagnostic criteria for bacterial suppurative arthritis include the demonstration of an inflammatory exudate by aspiration of synovial fluid and the isolation of bacteria from cultures of synovial fluid and/or blood. Clinical manifestations include joint effusion, swelling, tenderness, and pain, with or without redness of the overlying skin. Management consists of antimicrobial therapy, measures designed to relieve symptoms, surgical drainage of infected fluid, and physical therapy. Studies of new anti-infective therapy should be limited to cases of bacterial origin. Prospective, randomized, double-blind or evaluator-blinded, active-control comparative clinical trials should be performed. Clinical response is characterized as success (cure), failure, or indeterminate outcome. The most common successful microbiological outcome is presumptive eradication. Follow-up should continue for 1 year before the final assessment.
UR - http://www.scopus.com/inward/record.url?scp=0026448492&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026448492&partnerID=8YFLogxK
U2 - 10.1093/clind/15.Supplement_1.S172
DO - 10.1093/clind/15.Supplement_1.S172
M3 - Article
C2 - 1477226
AN - SCOPUS:0026448492
SN - 1058-4838
VL - 15
SP - S172-S176
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
ER -